Second TB vaccination boosts immunity in bladder cancer patients and reduces cancer recurrence
Reports and Proceedings
Updates every hour. Last Updated: 3-May-2025 13:09 ET (3-May-2025 17:09 GMT/UTC)
Two doses of a simple tuberculosis vaccination after surgery helps the immune system fight cancer cells and could greatly improve patient outcomes for the most common type of bladder cancer, according to a pilot study of 40 patients.
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that a new diagnosis of type 2 diabetes is linked to a subsequent increase in the risk of developing some, but not all, obesity related cancers. The study is by Owen Tipping, University of Manchester, UK, and Professor Andrew Renehan, National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester, UK, and colleagues.
Body size and excess weight, conventionally assessed using body mass index (BMI), are well-established risk factors for many types of cancer. However, new research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) and published in The Journal of the National Cancer Institute shows that waist circumference (WC) is a stronger risk marker than BMI for developing obesity-related cancers in men, but not women. The study was conducted by Dr. Ming Sun, Dr. Josef Fritz and Dr. Tanja Stocks, Lund University, Malmö, Sweden, and colleagues.
Treatment of B-cell Acute Lymphoblastic Leukaemia has been greatly improved by CAR-T therapies, but relapse is still very common. An international team has now found in animal models a new approach that offers “a promising therapeutic strategy”.
The results are published in ‘Blood’ by researchers from the Josep Carreras Leukaemia Research Institute and the Hospital Universitario 12 de Octubre – Spanish National Cancer Research Center (CNIO), among other institutions.
“Although in the preclinical stage, this research is a first step toward improving treatments for B-ALL patients”, authors say. “The goal is to enhance the effectiveness of CAR-T therapy and reduce relapses”.
Men who consistently avoid prostate cancer screening appointments face a disproportionately higher risk of dying from the disease, finds research identifying a new high-risk group.